Valuation : ABVC BioPharma, Inc.

Market Cap 25.92M 22.31M 20.99M 19.17M 35.87M 2.45B 35.96M 248M 96.24M 1.26B 97.35M 95.22M 4.05B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 28.65M 24.65M 23.2M 21.19M 39.64M 2.71B 39.75M 274M 106M 1.39B 108M 105M 4.47B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.7%
Yield 2024 *
-
Yield 2025 -
1 day-7.70%
1 week+11.18%
Current month+7.62%
1 month-13.76%
3 months-35.92%
6 months-36.36%
Current year-56.68%
1 week 0.82
Extreme 0.82
1.03
1 month 0.71
Extreme 0.7069
1.13
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.4
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 2023-06-22
Chief Executive Officer 39 2015-06-30
Chief Tech/Sci/R&D Officer 72 2023-06-12
Director TitleAgeSince
Chairman 39 2015-06-30
Director/Board Member 65 2017-11-22
Director/Board Member 55 2017-11-22
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/22 Other

Chairman

7,908,805 26.0954%
8/2/21 Other

Director

5,949 0.0243%
8/2/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-7.72%+11.18%-66.07%-21.80% 25.92M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.32%+6.36%-11.54%+378.12% 27.66B
+1.21%+2.33%+0.92%-14.38% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.31%+8.52%+58.08%+165.33% 14.65B
Average -2.00%+1.97%+32.86%+159.48% 28.32B
Weighted average by Cap. -1.51%-0.45%+39.10%+139.14%

Financials

2024 2025
Net sales 510K 439K 413K 377K 705K 48.11M 707K 4.88M 1.89M 24.69M 1.91M 1.87M 79.52M -
Net income -4.9M -4.22M -3.97M -3.63M -6.78M -463M -6.8M -46.91M -18.2M -238M -18.41M -18.01M -765M -7.91M -6.81M -6.4M -5.85M -10.94M -747M -10.97M -75.66M -29.36M -383M -29.7M -29.05M -1.23B
Net Debt 2.88M 2.48M 2.33M 2.13M 3.99M 272M 4M 27.57M 10.7M 140M 10.82M 10.59M 450M 2.73M 2.35M 2.21M 2.02M 3.77M 257M 3.78M 26.09M 10.12M 132M 10.24M 10.02M 426M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
26-09-04 US$0.9228 -7.72% 100,533
26-09-03 US$1.000 +15.67% 183,351
26-09-02 US$0.8645 +4.74% 138,161
26-09-01 US$0.8254 -3.74% 47,235
26-08-31 US$0.8575 +3.31% 113,480
  1. Stock Market
  2. Stocks
  3. ABVC Stock